Search the Newsreel

CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects.

CG Oncology's experimental drug cretositimogene grenadenorepvec (cret) has shown promising results in treating non-muscle invasive bladder cancer (NMIBC), achieving a 75% complete response rate and demonstrating a best-in-class safety profile with no severe adverse events. The company plans to submit a Biologics License Application …

CG Oncology Stock: Circling Back After Huge Rally (NASDAQ:CGON)

CGON (CGON) investor lists 25,989-share sale after series of stock disposals

An investor in CG Oncology, Inc. (CGON) has filed a Form 144, indicating a planned sale of 25,989 common shares with an aggregate market value of $1,973,970.86, expected on August 13, 2026. This filing also discloses a series of prior open-market sales by Ambaw …

CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position

A group of affiliated Wellington entities has disclosed a beneficial ownership of 5,324,751 shares of CG Oncology (CGON) common stock, representing 6.04% of the class. This disclosure, filed via a SCHEDULE 13G/A, indicates shared voting power over 4,637,354 shares and shared dispositive power over …

CG Oncology (CGON) Faces A Fair Value Gap Following Its Latest Earnings

CG Oncology recently reported its Q2 and H1 2026 earnings, showing revenue of US$1.16 million for the quarter and a net loss of US$79.06 million. Despite being a loss-making company, a discounted cash flow (DCF) model by Simply Wall St estimates a fair value …

CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise

An insider at CG Oncology, Ambaw Bellete, has filed to sell 32,137 common shares of CGON through Morgan Stanley Smith Barney LLC. This proposed sale is linked to a stock option exercise on August 12, 2026, with an aggregate market value of over $2.5 …

CGON (CGON) insider Ambaw Bellete plans 50,000-share stock sale

CG Oncology (CGON) insider Ambaw Bellete plans to sell 50,000 shares of common stock on August 11, 2026, through a stock option exercise settled in cash. The estimated value of this planned sale is $3,810,255.00. This disclosure also reveals several recent sales of CGON …

CG Oncology (NASDAQ:CGON) Hits New 52-Week High - Should You Buy?

CG Oncology (NASDAQ:CGON) recently reached a new 52-week high of $77.49, with a current trading price near $76.98. The clinical-stage biopharmaceutical company has a "Moderate Buy" consensus rating from analysts, with several price target increases, but reported a quarterly loss of $0.90 per share, …

CGON (CGON) insider plans 50,000-share stock sale after option exercise

CG Oncology, Inc. (CGON) filed a Form 144 indicating an insider's plan to sell 50,000 shares of common stock, valued at $3,770,580.00, on August 10, 2026, following a stock option exercise. The filing also details previous common stock sales by Ambaw Bellete over the …

Bank of America Securities Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)

Bank of America Securities reiterated a Buy rating on CG Oncology, Inc. (CGON) with an $88.00 price target. This affirmation follows the company's Q2 earnings report, which showed $1.16 million in revenue and a net profit of $0, a significant improvement from the prior …

Enterprise value to EBITDA forward of CG Oncology, Inc. – NASDAQ:CGON

This page from TradingView provides financial information for CG Oncology, Inc. (NASDAQ: CGON), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed at the time of viewing and presents various navigation options related to markets, products, and …

CG Oncology (NASDAQ:CGON) Posts Earnings Results, Misses Expectations By $0.24 EPS

CG Oncology (NASDAQ:CGON) reported a wider-than-expected quarterly loss of $0.90 per share, missing consensus estimates by $0.24, despite revenue of $1.16 million surpassing expectations. The stock saw a slight increase to $75.10, near its 52-week high, and maintains a "Moderate Buy" consensus rating with …

Insider Ambaw Bellete plans CGON (CGON) stock sale after large prior trades

Ambaw Bellete, an insider at CG Oncology, Inc. (CGON), has filed a Form 144 indicating an intent to sell up to 9,250 shares of common stock on August 7, 2026, through Morgan Stanley Smith Barney LLC. This filing also details several significant common stock …

Royal Bank Of Canada Has Lowered Expectations for CG Oncology (NASDAQ:CGON) Stock Price

Truist Financial Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price

BofA Adjusts Price Target on CG Oncology to $88 From $87

BofA Securities has raised its price target for CG Oncology (CGON) shares to $88 from $87, while maintaining a Buy rating. This adjustment follows a previous price target revision by RBC, which lowered its target to $79 from $81. The article highlights recent news …

How Investors Are Reacting To CG Oncology (CGON) Wider Quarterly Loss Amid Promising Phase 3 Bladder Cancer Data

CG Oncology recently reported a wider net loss of US$79.06 million in Q2 2026, while generating US$1.16 million in revenue. Despite the financial setback, the company is advancing its lead drug, cretostimogene grenadenorepvec, for non-muscle invasive bladder cancer, with promising Phase 3 data published …

CG Oncology, Inc. Stock 12‑Month Price Target Raised to $91.15, Implies 26% Upside

CG Oncology, Inc.'s average 12-month stock price target has increased from $90.69 to $91.15, based on estimates from 13 analysts, suggesting a 26% potential upside from its August 5 closing price. The consensus rating for CGON remains a "Buy" among 15 analysts, with 14 …

Insider (NASDAQ: CGON) files to sell 75,000 shares after recent stock sales

Ambaw Bellete, an insider at CG Oncology, Inc. (NASDAQ: CGON), has filed to sell 75,000 shares of common stock through Morgan Stanley's Executive Financial Services program, linked to a stock option exercise on August 6, 2026. This proposed sale has an aggregate market value …

CG Oncology earnings up next amid bladder cancer therapy push By Investing.com

CG Oncology Inc. is set to report second-quarter earnings, with analysts expecting a narrower loss as the company progresses towards a regulatory filing for its bladder cancer treatment. The biotech aims to complete its Biologics License Application by Q4 2026, positioning it for potential …

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) reported a Q2 loss of $0.9 per share, missing the Zacks Consensus Estimate of a $0.7 loss, and posted revenues of $1.16 million, which fell short of estimates by 59.02%. Despite the earnings miss, the company's shares have risen 74.4% …

Earnings Flash (CGON) CG Oncology, Inc. Reports Q2 Revenue $1.2M

CG Oncology (NASDAQ: CGON) posts $139.3M half-year loss with $1,028.3M cash

CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Inc. reported its second-quarter 2026 financial results, highlighting significant progress in clinical, regulatory, manufacturing, and commercial-readiness initiatives. Key milestones include anticipated Phase 3 topline data for PIVOT-006, expected BLA completion for HR BCG-unresponsive NMIBC in Q4 2026, and the publication of BOND-003 …

CG Oncology expects bladder cancer trial data soon; cash through 2029

CG Oncology reported a Q2 2026 net loss of $79.1 million on $1.2 million in revenue, primarily due to increased R&D and G&A expenses. The company maintains a strong cash position of approximately $1.0 billion, which is projected to fund operations through 2029, supporting …

CG Oncology (CGON) Earnings Date and Reports 2026

Dimensional Fund Advisors LP Sells 22,459 Shares of CG Oncology, Inc. $CGON

Dimensional Fund Advisors LP has reduced its stake in CG Oncology (NASDAQ:CGON) by selling 22,459 shares, though it still holds 438,673 shares valued at approximately $29.7 million. Despite this sale, institutional investors collectively own 26.56% of the company, and analysts maintain a "Moderate Buy" …

CGON (CGON) insider Ambaw Bellete plans 25,000-share stock sale via broker

CG Oncology, Inc. (CGON) insider Ambaw Bellete has filed a Form 144 notice to sell up to 25,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,837,500.00. The shares, acquired via a stock option exercise, are …

Price to earnings forward of CG Oncology, Inc. – NASDAQ:CGON

This article provides the "Price to earnings forward" metric for CG Oncology, Inc. (NASDAQ: CGON) on TradingView. It appears to be a financial data point displayed within a larger financial analysis platform. The specific value and change percentage are indicated as data fields.

CG Oncology (CGON) to Post Earnings on Friday

CGON|CG Oncology Inc|Price:69.180|Chg%:-3.440

This article provides a comprehensive stock analysis of CG Oncology Inc (CGON) from TradingKey. The company's fundamentals are considered healthy with high growth potential, and its valuation is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have given a "Buy" rating …

What CG Oncology (CGON)'s Pivotal BOND-003 Phase 3 Data Means For Shareholders

CG Oncology recently published pivotal Phase 3 BOND-003 data in The Lancet Oncology, showing that its monotherapy, cretostimogene grenadenorepvec, achieved significant complete responses with durable outcomes and a favorable safety profile for high-risk bladder cancer. This positive report strengthens the company's investment narrative by …

Law firm investigates CG Oncology officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating officers and directors of CG Oncology, Inc. for potential breaches of fiduciary duties through self-dealing. This probe could result in damages for shareholders and corporate governance reforms, and long-term shareholders are encouraged to contact the law firm.